Sommerfeld, L., Finkernagel, F., Jansen, J. M., Wagner, U., Nist, A., Stiewe, Müller-Brüsselbach, S., Sokol, A.M., Graumann, J., Reinartz, S. and Müller, R. (2021). The multicellular signaling network of ovarian cancer metastases. Clin. Transl. Med. 11, e633.

Dietze, R., Hammoud, M., Gómez-Serrano, M., Unger, A., Bieringer, T., Finkernagel, F., Sokol, A., Nist, A., Stiewe, T., Reinartz, S., Ponath, V., Preußer, C., Pogge von Strandmann, E., Müller-Brüsselbach, S., Graumann, J. and Müller, R. (2021). Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer. Theranostics 11: 1377-1395.



Ojasalu, K., Brehm, C., Hartung, K., Nischak, M., Finkernagel, F., Rexin, P., Nist, A., Pavlakis, E., Stiewe, T., Jansen, J.M., Wagner, U., Gattenlöhner, S., Bräuninger, S., Müller-Brüsselbach, S., Reinartz, S. and Müller, R. (2020). Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion. Mol. Oncol. 14: 2142–2162.

Steitz, A.M., Steffes, A., Finkernagel, F., Unger, A., Sommerfeld, L., H., Jansen, J.M., Wagner, U., Graumann, J., Müller, R. and Reinartz, S. (2020).

Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis. 11:249.


Graumann, J., Finkernagel, F., Reinartz, S., Stief, T., Brödje, D., Renz, H., Jansen, J.M., Wagner, U., Worzfeld, T., Pogge von Strandmann, E. and Müller, R. (2019). Multi-platform affinity proteomics identify proteins linked to metastasis and immune suppression in ovarian cancer plasma. Front. Oncol. 9:1150.

Finkernagel, F., Reinartz, S., Schuldner, M., Malz, A., Jansen, J.M., Wagner, U., Worzfeld, T., Graumann, J., Pogge von Strandmann, E. and Müller, R. (2019). Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment. Theranostics 19: 6601-6617. 

Reinartz, S., Lieber, S., Pesek, J., Brandt, D.T., Asafova, A., Finkernagel, F., Watzer, B., Nockher, W.A., Nist, A., Stiewe, T., Jansen, J.M., Wagner, U., Konzer, A., Graumann, J., Grosse, R., Worzfeld, T., Müller-Brüsselbach, S. and Müller, R. (2019) Cell-type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment. Mol. Oncol. 23: 185-201. 


Unger, A., Finkernagel, F., Hoffmann, N., Neuhaus, F., Joos, B., Nist, A., Stiewe, T., Visekruna, A., Wagner, U., Reinartz, S. Müller-Brüsselbach, S., Müller, R. and Adhikary, T. (2018). Chromatin Binding of c-REL and p65 Is Not Limiting for Macrophage IL12B Transcription During Immediate Suppression by Ovarian Carcinoma Ascites. Front Immunol. 9:1425.

Lieber, S., Reinartz, S., Raifer, H., Finkernagel, F., Dreyer, T., Bronger, H., Jansen, J.M., Wagner, U., Worzfeld, T., Müller, R. and Huber, M. (2018). Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. Oncoimmunology 7(5):e1424672. 


Worzfeld, T., Finkernagel, F., Reinartz, S., Konzer, K., Adhikary, T., Nist, A., Stiewe, T., Wagner, U., Looso, M., Graumann, J. and Müller, R. (2018). Proteotranscriptomics reveal signaling networks in the ovarian cancer microenvironment. Mol. Cell. Proteomics 17: 270-289.


Vyas, M., Reinartz, S., Hoffmann, N., Reiners, K.S., Lieber, S., Jansen, J.M., Wagner, U., Müller, R. and Pogge von Strandmann, E. (2017). Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D down-regulation. Oncoimmunology 6(9):e1339854.

Adhikary, T., Wortmann, A. , Finkernagel, F., Lieber, S., Nist, A., Stiewe, T., Wagner, U., Müller-Brüsselbach, S. Reinartz, S. and Müller, R. (2017). Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics 18: 243.


Worzfeld, T., Pogge von Strandmann, E.,  Huber, M., Adhikary, T., Reinartz, S., Wagner, U. and Müller, R. (2017).  The unique molecular and cellular microenvironment of ovarian cancer. Front. Oncol. 7, 24; DOI: 10.3389/fonc.2017.00024.

Vyas, M., Müller, R. and Pogge von Strandmann, E. (2017). Antigen loss variants: catching hold of escaping foes. Front. Immunol. 8;   DOI: 10.3389/fimmu.2017.00175

Pogge von Strandmann, E., Reinartz, S., Wagner, U. and Müller, R. (2017). Tumor-host cell interactions in ovarian cancer: pathways to therapy failure. Trends Cancer 3: 137-148.

Müller, R. (2017). PPARβ/δ in human cancer. Biochimie 136: 90-99.

Singh R., Dhanyamraju P.K. and Lauth M. (2017). DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway. Oncotarget 8: 833-845. 



Finkernagel, F., Reinartz, S., Lieber, S., Adhikary, T., Wortmann, A., Hoffman, N., Bieringer, T., Nist, A., Stiewe, T., Jansen, J.M., Wagner, U., Müller-Brüsselbach, S. and Müller, R. (2016). The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget 17: 75339-75352. 

Pogge von Strandmann, E. and Müller, R. (2016). Shipping drug resistance: Extracellular vesicles in ovarian cancer. Trends Mol. Med. 22: 741-743.

Reinartz, S., Finkernagel, F., Adhikary, T., Rohnalter, V., Schumann, T.,  Schober, Y., Nockher, A.W., Nist, A., Stiewe, T., Jansen, J.M., Wagner, U., Müller-Brüsselbach, S. and Müller, R. (2016). A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol. 17: 108. 


Rohnalter, V., Roth, K., Finkernagel, F., Adhikary, T., Obert, J., Dorzweiler, K., Bensberg, M., Müller-Brüsselbach, S. and Müller, R. (2015). A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget 6: 40005-40025. 

Adhikary, T., Wortmann, A., Schumann, T., Finkernagel, F., Lieber, S., Roth, K., Toth, P.M., Diederich, W.E., Nist, A., Stiewe, T., Kleinesudeik, L., Reinartz, S., Müller-Brüsselbach, S. and Müller, R. (2015). The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state. Nucl. Acids. Res. 43: 5033-5051.

Schumann, T.,  Adhikary, T., Wortmann, A., Finkernagel, F., Lieber, S., Schnitzer, E., Legrand, N., Schober, Y, Nockher, A. W., Toth, P.M., Diederich, W.E., Nist, A., Stiewe, T., Wagner, U., Reinartz, S., Müller-Brüsselbach, S. and Müller, R. (2015). Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget 6 13416-13433.


2014 and earlier


Reinartz, S., Schumann, T., Finkernagel, F., Wortmann, A., Jansen, J.M., Meissner, W., Krause, M., Schwörer, A.-M., Wagner, U., Müller-Brüsselbach, S. and Müller, R. (2014). Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int. J. Cancer 134: 32-42.

Baumann KH, Wagner U, du Bois A. (2012). The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol. 8: 1135-1147.

Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Oiccirillo, MC., Fossati, R., Gebski, V. and Lauraine, EP. (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and corboplatin in platinum-sensitive ovarian cacer patients, Br. J. Cancer 107, 588-591.

Reinartz, S., Failer, S., Schuell, T. and Wagner, U. (2012). CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur. J. Cancer 48: 1558-1569.

Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P.A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., Sehouli, J., Lortholary, A., Kristensen, G., Jackisch, C., Joly, F., Brown, C., Le Fur, N., du Bois, A. (2010). Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323-29.

Reinartz, S., Pfisterer, J., Du Bois, A., Jackisch, C., Baumann, K. H. and Wagner, U. (2010). Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment. Hum. Immunol. 71, 36-44.


Wagner, U., du Bois, A., Pfisterer, J., Huober, J., Loibl, S., Lück, H-J., Sehouli, J., Gropp, M., Stähle, A., Schmalfeldt, B., Meier, W., Jackisch, C. (2007). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – A phase II trial of the AGO-OVAR. Gynecol. Oncol. 105, 132-137.

Sabbatini, P., Dupont, J., Aghajanian, C., Derosa, F., Poynor, E., Anderson, S., Hensley, M., Livingston, P., Iasonos, A., Spriggs, D., McGuire, W., Reinartz, S., Schneider, S., Grande, C., Lele, S., Rodabaugh, K., Kepner, J., Ferrone, S. and Odunsi, K. (2006). Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res. 12, 5503-5510.


Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, A., Jacave A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., Olbricht, S. Le, T., Emerich, J., Kuhn, W., Bentley, J., Jakisch, Ch., Lück, H.-J., Rochon, J., Hayden Zimmermann, A., and Eisenhauer, E. (2006). Gemcitabine Plus Carboplatin Compared With Carboplatin In Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24, 1-10.


du Bois, A., Weber, B., Rochon, J., Meier, W., Goupil, A. Olbricht, S. Barats, J.-C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lück, H.-J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R. and Pujade-Leuraine, E. (2006). Addition of Epirubicin as a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarien Cancer: A Prophectively Randomized Gynecologic Cancer Intergroup Trial by the AGO-OVAR and the Groupe d´Investigateurs Nationaux pour I´Etude des Cancers Ovariens. J. Clin. Oncol. 24, 1127-11


du Bois, A., Belau, A., Wagner, U., Pfisterer, J., Schmalfeld, B., Richter, B., Staehle, A., Jackisch, C., Lueck, H. J., Schroeder, W., Burges, A., Olbricht, S., Elser, G., for the AGO-OVAR (2005). A phase II study of paclitaxel, carboplatin and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC  IV (AGO-OVAR protocol OVAR 8). Gynecol. Oncol. 96, 444-451.

Reinartz, S., Köhler, S., Schlebusch, H., Krista, K., Giffels, P., Renke, K., Huober, J., Mobus, V., Kreienberg, R., Dubois, A., Sabbatini, P. and Wagner, U. (2004). Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10, 1580-1587.


Reinartz, S., Hombach, A., Köhler, S., Schlebusch, H., Wallwiener, D., Abken, H. and Wagner, U. (2003). Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res. 63, 3234-3240.


Wagner, U., Köhler, S., Reinartz, S., Giffels, P., Huober, J., Renke, K., Schlebusch, H., Biersack, H.J, Möbus, V., Kreienberg, R., Bauknecht, T., Krebs, D. and Wallwiener, D. (2001). Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125 – Immune responses and survival in palliative treatment. Clin. Cancer Res. 7, 1154-1162.